Altered expression of HLA class I antigens in breast cancer:: Association with prognosis

被引:0
作者
Gudmundsdóttir, I
Jónasson, JG
Sigurdsson, H
Olafsdóttir, K
Tryggvadóttir, L
Ogmundsdóttir, HM
机构
[1] Iceland Canc Soc, Mol & Cell Biol Res Lab, IS-125 Reykjavik, Iceland
[2] Iceland Canc Soc, Iceland Canc Registry, Reykjavik, Iceland
[3] Univ Iceland, Dept Oncol, Reykjavik, Iceland
[4] Univ Iceland, Dept Pathol, Reykjavik, Iceland
关键词
D O I
10.1002/1097-0215(20001120)89:6<500::AID-IJC6>3.0.CO;2-#
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Loss of surface expression of class I major histocompatibility antigens is commonly observed in malignant tumors and has been considered one of the mechanisms for escape from cytotoxic T cells. However, natural killer cells kill cells lacking HLA class I antigens, In the present study, we characterized by immunohistochemistry the HLA class I expression of breast carcinomas from 187 patients with TNM stages I and II, diagnosed 1981-1984, using beta (2)-microglobulin as a marker and evaluated the effect on survival with a follow-up of up to 14 years. The largest group (48%) consisted of HLA class I-negative tumors (less than or equal to 10% of cells stained), mixed expression (> 10% and < 80% of cells stained) was seen in 36% and only 15% were classified as HLA class I-positive (greater than or equal to 80% cells stained). No associations could be established with various clinicopathological parameters, such as tumor size, presence of lymph node metastases, histological grade, expression of hormone receptors, S phase and p53 mutations. There was no effect on recurrence-free survival in the whole group; but among node-negative patients (n = 86), those who had tumors with mixed HLA class I expression had a significantly higher probability of disease recurrence (OR = 3.42, p 0.014) than patients with either HLA class I-positive or -negative tumors, particularly after more than 5 years. In node-positive patients who received adjuvant therapy, this phenotype was not associated with disease recurrence. Int. J. Cancer (Pred. Oncol,) 89:500-505, 2000, (C) 2000 Wiley-Liss, Inc.
引用
收藏
页码:500 / 505
页数:6
相关论文
共 39 条
[1]   COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].
BERGH, J ;
NORBERG, T ;
SJOGREN, S ;
LINDGREN, A ;
HOLMBERG, L .
NATURE MEDICINE, 1995, 1 (10) :1029-1034
[2]  
BONAL FJ, 1986, J IMMUNOGENET, V13, P179
[3]   High frequency of altered HLA class I phenotypes in invasive breast carcinomas [J].
Cabrera, T ;
Fernandez, MA ;
Sierra, A ;
Garrido, A ;
Herruzo, A ;
Escobedo, A ;
Fabra, A ;
Garrido, F .
HUMAN IMMUNOLOGY, 1996, 50 (02) :127-134
[4]  
Chen HL, 1996, INT J CANCER, V67, P756, DOI 10.1002/(SICI)1097-0215(19960917)67:6<756::AID-IJC2>3.0.CO
[5]  
2-Q
[6]  
CONCHA A, 1991, INT J CANCER, P146
[7]   SYNERGISTIC EFFECTS OF IL-6 AND IFN-GAMMA ON CARCINOEMBRYONIC ANTIGEN (CEA) AND HLA EXPRESSION BY HUMAN COLORECTAL-CARCINOMA CELLS - ROLE FOR ENDOGENOUS IFN-BETA [J].
DANSKYULLMANN, C ;
SALGALLER, M ;
ADAMS, S ;
SCHLOM, J ;
GREINER, JW .
CYTOKINE, 1995, 7 (02) :118-129
[8]   Regulation of major histocompatibility complex class I expression by NF-κB-related proteins in breast cancer cells [J].
Dejardin, E ;
Deregowski, V ;
Greimers, R ;
Cai, ZZ ;
Chouaib, S ;
Merville, MP ;
Bours, V .
ONCOGENE, 1998, 16 (25) :3299-3307
[9]   LACK OF HLA CLASS-I ANTIGEN EXPRESSION BY CULTURED MELANOMA-CELLS FO-1 DUE TO A DEFECT IN B2M GENE-EXPRESSION [J].
DURSO, CM ;
WANG, ZG ;
CAO, Y ;
TATAKE, R ;
ZEFF, RA ;
FERRONE, S .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (01) :284-292
[10]  
EYAL A, 1990, NAT IMMUN CELL GROW, V9, P222